Zilucoplan

Complement Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Zilucoplan is a drug in the Complement Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2023. Its mechanism of action is classified as Complement Inhibitors. DrugCentral lists 1 molecular target, including C5. Recorded indications include Generalized myasthenia gravis.

• Drug class: Complement Inhibitor.
• Mechanism of action: Complement Inhibitors.
• Molecular targets: C5 (1 listed in DrugCentral).
• Indications: Generalized myasthenia gravis.
• ATC code: L04AJ06 (Complement inhibitors).
• Molecular formula: C172H278N24O55; molecular weight 3562.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Generalized myasthenia gravis

Contraindications (1)

• Neisseria meningitidis infection

Mechanism & targets

• Mechanism of action (MoA): Complement Inhibitors
• Established pharmacologic class: Complement Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Complement C5	C5	inhibitor	Kd 9.37

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2023-10-17	FDA	—	UCB INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L04AJ06	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6
• FDA label: CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6
• HCSC label: CHRNA1, CHRNA3, CHRNA4, CHRNA5, CHRNA6

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myasthenia gravis crisis	95.2
Morvan syndrome	57.3
Myasthenia gravis	50.5
Morphoea	46.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Zilucoplan is on its molecule page.

• Molecular formula: C₁₇₂H₂₇₈N₂₄O₅₅
• Molecular weight: 3562.23 g/mol
• CAS number: —
• InChIKey: JDXCOXKBIGBZSK-PSNKNOTQSA-N
• PubChem CID: 133083018

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CNC2=NC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)N(C)C(=O)[C@@H]1CC(=O)NCCCC[C@H](NC(C)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N1)C(C)(C)C)C1CCCCC1)C(O)=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Zilucoplan used for?

DrugCentral lists the following indications for Zilucoplan: Generalized myasthenia gravis.

How does Zilucoplan work?

Zilucoplan is classified as Complement Inhibitors; its molecular targets in DrugCentral include C5 (inhibitor).

When was Zilucoplan first approved?

Zilucoplan was first approved by the FDA in 2023.

What drug class does Zilucoplan belong to?

Zilucoplan is in the Complement Inhibitor class.

What is the chemical formula of Zilucoplan?

Zilucoplan has the molecular formula C172H278N24O55 and a molecular weight of 3562.23 g/mol.

Sources

• DrugCentral drug card 5748 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4298207 — compound record and bioactivity
• PubChem CID 133083018 — chemical identifiers
• DrugBank DB15636 — drug record
• FDA UNII YG391PK0CC — substance identity
• DailyMed: FDA labels for Zilucoplan — current prescribing information (label search)
• UniProt P01031 (C5) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.